We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$961M
AUM Growth
+$374M
Cap. Flow
-$4.74M
Cap. Flow %
-0.49%
Top 10 Hldgs %
44.93%
Holding
194
New
69
Increased
29
Reduced
39
Closed
48

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$24.6M
2
AGN
Allergan plc
AGN
+$24.2M
3
MRK icon
Merck
MRK
+$22.3M
4
AMGN icon
Amgen
AMGN
+$17.6M
5
ENDP
Endo International plc
ENDP
+$17.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$33.6M
2
SHPG
Shire pic
SHPG
+$20.7M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.2M
4
BIIB icon
Biogen
BIIB
+$11.8M
5
ISRL
Isramco Inc
ISRL
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 53.73%
2 Technology 2.61%
3 Industrials 1.8%
4 Consumer Discretionary 1.51%
5 Utilities 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
101
Rocket Pharmaceuticals
RCKT
$340M
$2.17M 0.23%
+100,000
New +$2.35M
SMMT icon
102
Summit Therapeutics
SMMT
$10.4B
$2.17M 0.23%
+175,000
New +$1.98M
ITB icon
103
iShares US Home Construction ETF
ITB
$2.26B
$2.15M 0.22%
+76,000
New +$2.03M
BKNG icon
104
Booking.com
BKNG
$149B
$2.12M 0.22%
+45,500
New +$2.04M
WAB icon
105
Wabtec
WAB
$49.1B
$2.04M 0.21%
+21,500
New +$1.94M
SRCL
106
DELISTED
Stericycle Inc
SRCL
$2.04M 0.21%
+14,500
New +$1.96M
TRIL
107
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.92M 0.2%
+95,000
New +$1.4M
MRNS
108
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.92M 0.2%
53,383
-20,000
-27% -$878K
UNP icon
109
Union Pacific
UNP
$174B
$1.89M 0.2%
17,489
-8,200
-32% -$962K
ELLO icon
110
Ellomay Capital Ltd
ELLO
$270M
$1.88M 0.2%
221,678
+17,900
+9% +$161K
MGNX icon
111
MacroGenics
MGNX
$235M
$1.88M 0.2%
60,000
-24,198
-29% -$820K
ZSAN
112
DELISTED
Zosano Pharma Corporation
ZSAN
$1.87M 0.19%
+264
New +$1.98M
TTHI
113
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$1.86M 0.19%
+272,906
New +$1.89M
FOMX
114
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.85M 0.19%
+200,000
New +$1.79M
THRM icon
115
Gentherm
THRM
$1.25B
$1.75M 0.18%
+34,550
New +$1.46M
CLLS
116
Cellectis
CLLS
$277M
$1.73M 0.18%
+50,000
New +$1.81M
ELDN icon
117
Eledon Pharmaceuticals
ELDN
$261M
$1.65M 0.17%
903
-47
-5% -$104K
HSTO
118
DELISTED
Histogen Inc. Common Stock
HSTO
$1.57M 0.16%
+1,100
New +$1.4M
MNKD icon
119
PUT
MannKind Corp
MNKD
$1.21B
$1.56M 0.16%
600
-59,400
-99% -$1.79M
GNVC
120
DELISTED
GenVec, Inc.
GNVC
$1.56M 0.16%
52,833
-3,000
-5% -$98.6K
OCRX
121
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.51M 0.16%
321,254
-100,000
-24% -$576K
GALT icon
122
Galectin Therapeutics
GALT
$196M
$1.51M 0.16%
+450,000
New +$1.61M
GNCA
123
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.47M 0.15%
+15,525
New +$1.1M
GNMX
124
DELISTED
Aevi Genomic Medicine Inc
GNMX
$1.41M 0.15%
175,000
-50,000
-22% -$377K
LUMO
125
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.37M 0.14%
2,778
– –
3 4
5
6 7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sphera Funds Management held 194 positions worth $961M, up 64% from $587M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management's Q1 2015 filing shows 69 new, 29 increased, 39 reduced and 48 closed positions. Its largest new stake was AbbVie: 407,000 shares worth $23.8M. The largest sale was Novartis, an estimated $33.6M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 63% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q1 2015 buy was AbbVie: 407,000 shares worth $23.8M.
  • Sphera Funds Management added most to Allergan plc in Q1 2015, an estimated $24.2M increase.
  • Sphera Funds Management's biggest Q1 2015 reduction was Novartis, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q1 2015, selling an estimated $18.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $961M portfolio in Q1 2015.
  • Sphera Funds Management opened 69 new positions and closed 48 in Q1 2015.
  • Sphera Funds Management's portfolio value rose 64% quarter-over-quarter to $961M.

Based on Sphera Funds Management's 13F filing for Q1 2015, filed 11 May 2015.